{"id":100826,"date":"2026-08-11T13:03:09","date_gmt":"2026-08-11T11:03:09","guid":{"rendered":"https:\/\/www.veeva.com\/eu\/?post_type=resources&#038;p=100826"},"modified":"2026-08-11T10:01:46","modified_gmt":"2026-08-11T08:01:46","slug":"veeva-vault-crm-selected-by-eli-lilly-and-company","status":"publish","type":"resources","link":"https:\/\/pantheon.veeva.com\/eu\/resources\/veeva-vault-crm-selected-by-eli-lilly-and-company\/","title":{"rendered":"Veeva Vault CRM Selected by Eli Lilly and Company"},"content":{"rendered":"<p>\n<strong>PLEASANTON, CA \u2014 August 11, 2026 \u2014 <\/strong> <a href=\"\/\" target=\"_blank\" rel=\"noreferrer noopener\">Veeva Systems<\/a> (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has committed to <a href=\"\/eu\/products\/crm-suite\/crm\/\">Veeva Vault CRM<\/a> globally.<\/p>\n<p>\nVault CRM is part of the Vault CRM Suite of applications that provides the technology foundation for agentic commercial, the new commercial model that leverages AI to get the right medicines to more patients.\n<\/p>\n<p>\n\u201cWe are excited to expand our strategic work with Veeva by moving to Vault CRM,\u201d said Giuseppe Firenze, senior vice president, U.S. HCP and field engagement hub at Lilly. \u201cVault CRM will help Lilly bring our breakthrough medicines to more patients.\u201d\n<\/p>\n<p>\n\u201cLilly creates medicines that make life better for people around the world,\u201d said Veeva CEO Peter Gassner. \u201cWe are proud to expand our strategic work with Lilly as they roll out Vault CRM globally.\u201d\n<\/p>\n<p>\nLearn more about Veeva Vault CRM Suite, including the <a href=\"\/eu\/products\/commercial-cloud\/\">Agentic Call Report<\/a> to generate Commercial Evidence, at <a href=\"\/eu\/products\/crm-suite\/crm\/\">veeva.com\/eu\/crm<\/a>.<\/p>\n<p>\n<strong>About Veeva Systems<\/strong> <br \/>\nVeeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world&#8217;s largest pharmaceutical companies to emerging biotechs. As a <a href=\"\/pbc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Public Benefit Corporation<\/a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href=\"\/eu\/\"> <\/a>veeva.com\/eu.\n<\/p>\n<p>\n<strong>Veeva Forward-Looking Statements<\/strong> <br \/>\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended April 30, 2026, which you can find <a href=\"https:\/\/www.sec.gov\/ixviewer-plus\/ix.xhtml?doc=\/Archives\/edgar\/data\/0001393052\/000139305226000026\/veev-20260430.htm#i7e129a0ad48d459ea13c21cd7e2de073_124\" target=\"_blank\" rel=\"noreferrer noopener\">here<\/a> (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at <a href=\"https:\/\/www.sec.gov\/\" target=\"_blank\" rel=\"noreferrer noopener\">sec.gov<\/a>.\n<\/p>\n<\/p>\n<p><center>###<\/center><\/p>\n<p>\n<strong>Contact:<\/strong>\n<\/p>\n<p>\nMeera Lakhani-Patel<br \/>\nVeeva Systems, Europe<br \/>\n<a href=\"mailto:meera.lakhani-patel@veeva.com\">meera.lakhani-patel@veeva.com<\/a>\n<\/p>\n<p>\nMaria Scurry<br \/>\nVeeva Systems<br \/>\n<a href=\"mailto:maria.scurry@veeva.com\">maria.scurry@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company commits to Veeva Vault CRM globally to help bring breakthrough medicines to more patients.<\/p>\n","protected":false},"featured_media":100972,"parent":0,"template":"","class_list":["post-100826","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-area-20-commercial","resource-product-20-crm","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/100826"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":5,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/100826\/revisions"}],"predecessor-version":[{"id":100975,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/100826\/revisions\/100975"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/media\/100972"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=100826"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}